Gene-Directed Enzyme Pro-drug Therapy: A Promising Way for Cancer Treatment

Abstract

Gene-directed protein prodrug medical aid (GDEPT) may be a promising strategy that aims to limit the general toxicity associate degreed improve the property of therapy use through the expression of a factor that encodes associate degree catalyst that converts nontoxic prodrug into an activated cytotoxic agent. It offers a brand new approach to treating some cancers. Clinical trials are completed for brain and prostate cancers and also the initial product for post-surgical treatment of some brain tumors is awaiting selling approval. Recent innovations offer a glimpse into the doable future evolution of a brand new cistron medication [1].